NCT00373516View on ClinicalTrials.gov

Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 30, 2004

Study Completion Date

March 31, 2005

Conditions
Psoriasis
Interventions
DRUG

Vehicle (Placebo) applied BID

DRUG

QRX-101 75 mcg/g ointment applied QD

DRUG

QRX-101 75 mcg/g ointment applied BID

Trial Locations (12)

19560

Clinical Research Site, Temple

27157

Clinical Research Site, Winston-Salem

29621

Clinical Research Site, Anderson

29681

Clinical Research Site, Simpsonville

40217

Clinical Research Site, Louisville

40509

Clinical Research Site, Lexington

48109

Clinical Research Site, Ann Arbor

55435

Clinical Research Site, Edina

66215

Clinical Research Site, Overland Park

71913

Clinical Research Site, Hot Springs

78229

Clinical Research Site, San Antonio

95404

Clinical Research Site, Santa Rosa

All Listed Sponsors
lead

QuatRx Pharmaceuticals Company

INDUSTRY

NCT00373516 - Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis | Biotech Hunter | Biotech Hunter